Pierre Catignol explains how the conventional model creates friction when the industry needs fluidity, and integrated manufacturing answers that call by converting logistical complexity into a reliable operating rhythm that clients trust.
Ashwin Agarwal, CFO of Azura Ophthalmics and John Merhige, Co-CEO of Credence MedSystems, share an inside look at how two partners are aligning technical and regulatory strategies, integrating complementary expertise, and collaborating effectively to deliver an innovative ophthalmic combination product and inform future biotech–device partnerships.
Drs. Rotem Gura-Sadovsky and Maayan Eilon-Ashkenazy explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
Andrew Parker, PhD, John McDermott, and Sandeep Kumar, PhD, believe the development of poorly soluble drugs remains a significant challenge in pharmaceutical R&D. However, by adopting an adaptive approach that integrates services from preclinical screening to clinical optimization, developers can achieve significant time- and cost-saving benefits.
Kim Shepard, Director of Advanced Drug Delivery at Lonza, and Carsten Rudolph, PhD, Co-founder and Chief Executive Officer at Ethris, discuss the main objectives of the collaboration and the benefits of spray-dried mRNA vaccines.
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
COMPANY PROFILE
HCmed Innovations is a CDMO specializing in inhalation drug delivery systems. Leveraging our proprietary vibrating mesh technology, we provide an integrated platform for the development of drug-device combination products, offering customized solutions for pharmaceutical partners. HCmed provides full-spectrum support from early-stage feasibility through clinical trials and commercial supply. Our integrated approach ensures alignment between drug formulation and device performance, allowing seamless transition across development phases. Whether optimizing aerosol characteristics or supporting regulatory submissions, we help partners de-risk development and shorten timelines for bringing combination products to market. Click here for more.
Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.
The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …
Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
February 4 – Analytical Testing
February 11 – Injection Devices